FIGURE LEGEND
Figure 1 : Diabetic parameters in experimental groups.Fasting blood glucose (A), hemoglobin A1c (B), serum
insulin level (C) and HOMA Index at the end of the 8-week experimental
protocol. *p<0.05 vs. lean ZSF1-Vehicle; ‡p<0.05 vs.
obese ZSF1-Vehicle. ENAL = enalapril. Data are reported as box and
whisker plots with median, minimum to maximum, and 10 to 90 percentiles,
n=6/group.
Figure 2 : Circulating lipids in experimental groups.Plasma levels of cholesterol (A), non-esterified free fatty acid (B),
triglyceride (C), and LDL-cholesterol (D) at the end of the 8-week
experimental protocol. *p<0.05 vs. lean ZSF1-Vehicle;
‡p<0.05 vs. obese ZSF1-Vehicle. ENAL = enalapril. Data are
reported as box and whisker plots with median, minimum to maximum, and
10 to 90 percentiles, n=6/group.
Figure 3 : Renal injury in experimental groups.Calculated values of renal cortical (A) and medullary (B) cast area at
the end of the 8-week experimental protocol. Albuminuria (C) and a
representative photomicrograph showing tubular cast in the renal cortex
and medulla (arrows) of different experimental groups analyzed at the
end of the protocol (D). *p<0.05 vs. lean ZSF1-Vehicle;
‡p<0.05 vs. obese ZSF1-Vehicle. ENAL = enalapril. Data are
reported as box and whisker plots with median, minimum to maximum, and
10 to 90 percentiles, n=6/group.
Figure 4 : Glomerular injury in experimental groups.Calculated values of glomerular injury score (A) and glomerular nephrin
expression (C) at the end of the 8-week experimental protocol.
Representative photomicrograph showing damaged glomeruli (arrows) (B)
and nephrin expression (arrows) in the glomeruli of different
experimental groups analyzed at the end of the protocol (D).
*p<0.05 vs. lean ZSF1-Vehicle; ‡p<0.05 vs. obese
ZSF1-Vehicle. ENAL = enalapril. Data are reported as box and whisker
plots with median, minimum to maximum, and 10 to 90 percentiles,
n=6/group. Dual acting sEH-COX-2 inhibitor PTUPB attenuated angiotensin
II (ANG II)-induced glomerular albumin permeability (E).
*p<0.05 vs. Baseline; ‡p<0.05 vs. ANG II-PTUPB. Data
for E are expressed as mean ± SEM, n=10/group
Figure 5 : Kidney inflammation in experimental groups.Urinary excretion of MCP-1 (A), CD-68 positive inflammatory cells in the
kidney (B), and representative photomicrograph depicting CD-68 positive
cells in the kidney (C) at the end of the 8-week experimental protocol.
*p<0.05 vs. lean ZSF1-Vehicle; ‡p<0.05 vs. obese
ZSF1-Vehicle. ENAL = enalapril. Data are reported as box and whisker
plots with median, minimum to maximum, and 10 to 90 percentiles,
n=6/group.
Figure 6 : Kidney fibrosis in experimental groups.Calculated values of renal cortical (A), medullary (B) collagen positive
fibrotic area, and a representative photomicrograph showing renal
fibrosis (C) at the end of the 8-week experimental protocol.
*p<0.05 vs. lean ZSF1-Vehicle; ‡p<0.05 vs. obese
ZSF1-Vehicle. ENAL = enalapril. Data are reported as box and whisker
plots with median, minimum to maximum, and 10 to 90 percentiles,
n=6/group.
Figure 7 : Liver injury in experimental groups. Plasma
levels of AST (A), ALT (B), calculated value of liver collagen positive
area (C) and representative photomicrograph depicting collagen positive
area (arrows) in the liver (E) at the end of the 8-week experimental
protocol. Calculated values of oil o red positive (steatosis) liver area
(D) and a representative photomicrograph liver steatosis (arrows)
obtained from oil o red staining at the end of the 8-week experimental
protocol (F). *p<0.05 vs. lean ZSF1-Vehicle; ‡p<0.05
vs. obese ZSF1-Vehicle. ENAL = enalapril. Data are reported as box and
whisker plots with median, minimum to maximum, and 10 to 90 percentiles,
n=6/group.